BioCentury | Dec 31, 2016
Finance

Seeking Harbour

...Ablynx N.V. (Euronext:ABLX), a public company valued at €660 million ($690 million). The other is Ossianix Inc....
BioCentury | Sep 29, 2014
Emerging Company Profile

Ossianix: Shark teeth

...biologics that are unmet needs, particularly in difficult targets in the central nervous system," said Ossianix...
...now part of Pfizer Inc. Unlike a traditional antibody, which comprises heavy and light chains, Ossianix's...
...Ossianix. In 2014, Lundbeck re-upped its partnership with a specific focus in two areas, and Ossianix...
BioCentury | Jan 13, 2014
Company News

Ossianix, Lundbeck deal

...The companies partnered for two projects using Ossianix's single domain antibody platform based on shark variable...
...based on shark variable new antigen receptor (VNAR) technology. The first project will further develop Ossianix's...
...preclinical animal testing this year. The second project is to develop bispecific products comprised of Ossianix's...
BioCentury | Jun 6, 2013
Distillery Techniques

Technology: Drug platforms

...described VNARs. Next steps could include generating humanized shark VNARs against known disease targets. Separately, Ossianix Inc....
BioCentury | Jul 2, 2012
Financial News

Ossianix completes venture financing

Ossianix Inc. , Philadelphia, Pa. Business: Antibodies Date completed: 6/18/12 Type: Venture financing Raised: $65,000 Investor: BioAdvance WIR Staff...
BioCentury | Jan 9, 2012
Company News

Ossianix, Lundbeck deal

...Ossianix said it partnered with H. Lundbeck to discover therapeutics for CNS diseases. Ossianix raised an...
...committee with representatives from both companies will have oversight of products developed under the deal. Ossianix...
...and co-founder and managing director of venBio. Ossianix investors include BioAdvance and the ALS Association. Ossianix Inc....
BioCentury | Jan 5, 2012
Company News

Ossianix, Lundbeck in CNS deal

...Pa.) said it partnered with H. Lundbeck A/S (CSE:LUN) to discover therapeutics for CNS diseases. Ossianix...
...also will have non-exclusive rights to negotiate a license on technologies arising from the deal. Ossianix...
...of Pfizer Inc. (NYSE:PFE). Goodman is Ossianix's chairman and co-founder and managing director of venBio. Ossianix...
BioCentury | Mar 14, 2011
Company News

Covagen board of directors update

...Zurich, Switzerland Business: Inflammation, Cancer, Autoimmune Appointed: Frank Walsh as executive chairman, currently CEO of Ossianix Inc. WIR...
Items per page:
1 - 8 of 8
BioCentury | Dec 31, 2016
Finance

Seeking Harbour

...Ablynx N.V. (Euronext:ABLX), a public company valued at €660 million ($690 million). The other is Ossianix Inc....
BioCentury | Sep 29, 2014
Emerging Company Profile

Ossianix: Shark teeth

...biologics that are unmet needs, particularly in difficult targets in the central nervous system," said Ossianix...
...now part of Pfizer Inc. Unlike a traditional antibody, which comprises heavy and light chains, Ossianix's...
...Ossianix. In 2014, Lundbeck re-upped its partnership with a specific focus in two areas, and Ossianix...
BioCentury | Jan 13, 2014
Company News

Ossianix, Lundbeck deal

...The companies partnered for two projects using Ossianix's single domain antibody platform based on shark variable...
...based on shark variable new antigen receptor (VNAR) technology. The first project will further develop Ossianix's...
...preclinical animal testing this year. The second project is to develop bispecific products comprised of Ossianix's...
BioCentury | Jun 6, 2013
Distillery Techniques

Technology: Drug platforms

...described VNARs. Next steps could include generating humanized shark VNARs against known disease targets. Separately, Ossianix Inc....
BioCentury | Jul 2, 2012
Financial News

Ossianix completes venture financing

Ossianix Inc. , Philadelphia, Pa. Business: Antibodies Date completed: 6/18/12 Type: Venture financing Raised: $65,000 Investor: BioAdvance WIR Staff...
BioCentury | Jan 9, 2012
Company News

Ossianix, Lundbeck deal

...Ossianix said it partnered with H. Lundbeck to discover therapeutics for CNS diseases. Ossianix raised an...
...committee with representatives from both companies will have oversight of products developed under the deal. Ossianix...
...and co-founder and managing director of venBio. Ossianix investors include BioAdvance and the ALS Association. Ossianix Inc....
BioCentury | Jan 5, 2012
Company News

Ossianix, Lundbeck in CNS deal

...Pa.) said it partnered with H. Lundbeck A/S (CSE:LUN) to discover therapeutics for CNS diseases. Ossianix...
...also will have non-exclusive rights to negotiate a license on technologies arising from the deal. Ossianix...
...of Pfizer Inc. (NYSE:PFE). Goodman is Ossianix's chairman and co-founder and managing director of venBio. Ossianix...
BioCentury | Mar 14, 2011
Company News

Covagen board of directors update

...Zurich, Switzerland Business: Inflammation, Cancer, Autoimmune Appointed: Frank Walsh as executive chairman, currently CEO of Ossianix Inc. WIR...
Items per page:
1 - 8 of 8